Short reportsExtrinsic-pathway activation in cancer with high factor Vlla and tissue factor
References (11)
Cancer cell procoagulants and their implications
Hematol Clin North Am
(1992)- et al.
Myeloproliferative and metabolic causes of thrombophilia
Clin Haematol
(1994) Cancer and thrombosis
Haemostasis
(1994)- et al.
Tissue factor expression correlates with histological grade in human pancreatic carcinoma
Br J Surg
(1995) - et al.
Tissue factor in microvesicles shed from U87Mg human glioblastoma cells induces coagulation platelet aggregation and thrombogenesis
Blood
(1994)
Cited by (218)
Tumor-educated platelets
2024, Clinica Chimica ActaPlatelet activation status in the diagnosis and postoperative prognosis of hepatocellular carcinoma
2019, Clinica Chimica ActaCitation Excerpt :In the exogenous coagulation pathway, factor VII (with tissue factor) acts as the main activator and participates in the entire exogenous coagulation. It has been reported that factor VII is greatly increased in tumor patients, thereby activating thrombin release [3]. The venous thromboembolism has been shown a risk factor for tumor prognosis [4,5].
Diagnosis, Treatment, and Prevention of Cancer-Associated Thrombosis
2019, Abeloff’s Clinical OncologyExtracellular vesicles exposing tissue factor for the prediction of venous thromboembolism in patients with cancer: A prospective cohort study
2018, Thrombosis ResearchCitation Excerpt :Tumor-derived EV exposing TF (EV-TF) have been proposed to contribute to cancer-associated VTE [6]. The transmembrane protein TF, which is the main initiator of the coagulation pathway, is overexpressed in various types of cancer and can promote tumor growth and metastasis [7–9]. When tumor cells release EV-TF into the blood, these TF-positive EVs can activate coagulation and predispose cancer patients to VTE.